Y Y Janjigian

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 54:936-43. 2013
  2. doi request reprint Genomic dysregulation in gastric tumors
    Yelena Y Janjigian
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College of Cornell University, New York, New York 10065, USA
    J Surg Oncol 107:237-42. 2013
  3. ncbi request reprint Molecularly targeted therapies in advanced gastric cancer
    Y Y Janjigian
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Minerva Gastroenterol Dietol 57:75-88. 2011
  4. pmc MET expression and amplification in patients with localized gastric cancer
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 20:1021-7. 2011
  5. doi request reprint Tobacco use is associated with increased recurrence and death from gastric cancer
    E C Smyth
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:2088-94. 2012
  6. ncbi request reprint Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma
    N Gerber
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Esophagus 27:235-41. 2014
  7. ncbi request reprint Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
    Y Y Janjigian
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College of Cornell University, New York, USA
    Ann Oncol 23:2656-62. 2012

Collaborators

Detail Information

Publications7

  1. doi request reprint Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 54:936-43. 2013
    ....
  2. doi request reprint Genomic dysregulation in gastric tumors
    Yelena Y Janjigian
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College of Cornell University, New York, New York 10065, USA
    J Surg Oncol 107:237-42. 2013
    ..This review summarizes the genetic and epigenetic changes thought to drive gastric cancer and the emerging paradigm of gastric cancer as three unique disease subtypes...
  3. ncbi request reprint Molecularly targeted therapies in advanced gastric cancer
    Y Y Janjigian
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Minerva Gastroenterol Dietol 57:75-88. 2011
    ..The results of the clinical trials evaluating these agents, including completed and ongoing evaluations, are summarized...
  4. pmc MET expression and amplification in patients with localized gastric cancer
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 20:1021-7. 2011
    ..MET, the receptor for hepatocyte growth factor, has been proposed as a therapeutic target in gastric cancer. This study assessed the incidence of MET expression and gene amplification in tumors of Western patients with gastric cancer...
  5. doi request reprint Tobacco use is associated with increased recurrence and death from gastric cancer
    E C Smyth
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:2088-94. 2012
    ..We examined the hypothesis that gastric cancer developing in patients with a history of tobacco use may be associated with increased risk of cancer-specific death after curative surgical resection...
  6. ncbi request reprint Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma
    N Gerber
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Esophagus 27:235-41. 2014
    ..The use of IMRT may allow for integration of more intensified systemic therapy or radiation dose escalation for esophageal adenocarcinoma, ultimately improving outcomes for patients with this aggressive disease. ..
  7. ncbi request reprint Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
    Y Y Janjigian
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College of Cornell University, New York, USA
    Ann Oncol 23:2656-62. 2012
    ..To determine whether human epidermal growth factor receptor 2 (HER2) status is an independent prognostic factor in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma...